FY2025 Earnings Estimate for CNTA Issued By Chardan Capital

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) – Equities researchers at Chardan Capital decreased their FY2025 EPS estimates for Centessa Pharmaceuticals in a report released on Wednesday, August 13th. Chardan Capital analyst R. Li now anticipates that the company will post earnings of ($1.50) per share for the year, down from their prior estimate of ($1.20). Chardan Capital currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share.

Other analysts have also issued reports about the stock. Needham & Company LLC initiated coverage on shares of Centessa Pharmaceuticals in a research note on Wednesday, May 28th. They issued a “buy” rating and a $35.00 price objective for the company. Oppenheimer initiated coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, May 8th. They issued an “outperform” rating and a $6.00 price objective for the company. Truist Financial initiated coverage on shares of Centessa Pharmaceuticals in a research note on Monday, July 21st. They issued a “buy” rating and a $30.00 price objective for the company. Finally, Wall Street Zen lowered shares of Centessa Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. One investment analyst has rated the stock with a sell rating and eleven have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $28.10.

Centessa Pharmaceuticals Stock Up 2.3%

NASDAQ:CNTA opened at $18.05 on Monday. Centessa Pharmaceuticals has a 1-year low of $9.60 and a 1-year high of $19.09. The company has a 50-day moving average of $14.76 and a 200 day moving average of $14.48. The firm has a market cap of $2.42 billion, a PE ratio of -10.08 and a beta of 1.48. The company has a debt-to-equity ratio of 0.32, a current ratio of 10.11 and a quick ratio of 10.12.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03).

Insiders Place Their Bets

In other news, insider Mario Alberto Accardi sold 15,000 shares of the stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $14.00, for a total transaction of $210,000.00. Following the transaction, the insider owned 216,485 shares in the company, valued at $3,030,790. This trade represents a 6.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $12.63, for a total value of $694,650.00. Following the transaction, the chief executive officer owned 221,017 shares in the company, valued at $2,791,444.71. This trade represents a 19.93% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 236,322 shares of company stock worth $3,300,064. Corporate insiders own 7.09% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CNTA. Janus Henderson Group PLC lifted its position in shares of Centessa Pharmaceuticals by 279.2% during the 4th quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock valued at $82,218,000 after buying an additional 3,614,623 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its stake in Centessa Pharmaceuticals by 35.8% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 6,954,000 shares of the company’s stock valued at $99,999,000 after purchasing an additional 1,834,973 shares during the last quarter. Foresite Capital Management VI LLC acquired a new position in Centessa Pharmaceuticals in the 4th quarter valued at $20,994,000. Balyasny Asset Management L.P. acquired a new position in Centessa Pharmaceuticals in the 2nd quarter valued at $16,052,000. Finally, Commodore Capital LP raised its stake in Centessa Pharmaceuticals by 39.3% in the 2nd quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock valued at $43,340,000 after purchasing an additional 930,711 shares during the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.